Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates Life Science Investing
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer Biotech Investing
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ for Breast Cancer Biotech Investing
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy Genetics Investing
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025 Life Science Investing
